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Abstract
Cisplatin (CDDP) intravenous treatments suffer several dose-limiting toxicity issues. Hyaluronan
(HA), a naturally occurring biopolymer in the interstitium, is primarily cleared by the lymphatic
system. An alteration in input rate and administration route through pulmonary delivery of
hyaluronan-cisplatin conjugate (HA-Pt) may increase local lung CDDP concentrations and decrease
systemic toxicity.
Sprague-Dawley rats were split into four groups: i.v. CDDP (3.5 mg/kg), i.v. HA-Pt conjugate (3.5
mg/kg equivalent CDDP), lung instillation CDDP and lung instillation HA-Pt conjugate. Total
platinum level in the lungs of the HA-Pt lung instillation group was 5.7-fold and 1.2-fold higher than
the CDDP intravenous group at 24 h and 96 h, respectively. A 1.1-fold increase of Pt accumulation
in lung draining nodes for the HA-Pt lung instillation group was achieved at 24 h relative to the
CDDP i.v. group. In the brain and kidneys, the CDDP i.v. group had higher tissue/plasma ratios
compared to the HA-Pt lung instillation group. Augmented tissue distribution from CDDP i.v. could
translate into enhanced tissue toxicity compared to the altered input rate and distribution of the
intrapulmonary nanoformulation.
In conclusion, a local pulmonary CDDP delivery system was developed with increased platinum
concentration in the lungs and draining nodes compared to i.v. therapy.
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1. Introduction
Cisplatin (cis-diamminedichloroplatinum or CDDP) is an extensively employed
chemotherapeutic agent for the treatment of a wide spectrum of solid tumors. CDDP-based
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therapies have been shown to be more effective in the treatment of lung cancer compared to
other platinum chemotherapeutics, such as carboplatin (Hotta et al., 2004; Zatloukal et al.,
2003). However, CDDP administered intravenously can cause severe side effects including
increased risks of leucopenia, nausea, anemia, acute nephrotoxicity, and chronic neurotoxicity
(both hearing loss and nerve damage) (Carrick et al., 2004; Chu, 1994; Ihde et al., 1994; Perng
et al., 1997). These detrimental side effects can lead to decreased patient compliance, inability
to complete chemotherapy courses, or use of less effective chemotherapeutic agents. Moreover,
untargeted chemotherapeutics that are delivered intravenously result in relatively low
concentrations of drug that reaches the lung tumor compared to cytotoxin susceptible tissues
and organs. This ultimately decreases the chances of successful control of the tumor and
increases the risks of adverse toxicity events in patients due to wide distribution of the drug.
Many efforts have been made to reduce the systemic side effects while retaining the potency
of CDDP in treatment regimens including: combination therapy, encapsulation of CDDP in
liposomes (Kim et al., 2001) and micelles (Nishiyama et al., 2003), and regional delivery of
CDDP by pulmonary arterial infusion (Brown et al., 2006; Devarajan et al., 2004; Junior et al.,
2007). Pulmonary delivery of chemotherapeutics has become of topical interest as a non-
invasive route of administration for local delivery to the lungs (Gagnadoux et al., 2008; Selting
et al., 2008). This route of administration may increase drug concentration in the lungs and
reduce overall systemic side effects, which could greatly benefit both early stage patients with
locoregional disease and advanced patients requiring less harmful palliative care.
Localization of drug not only to the cancerous cells, but also to the surrounding lymph nodes
is essential in treatment and prevention of cancer cell metastasis. Hyaluronan (HA) is a
naturally occurring polysaccharide found in the connective tissues and is primarily cleared by
the lymphatic system (Fraser and Laurent, 1989). Conjugation of CDDP to HA may result in
localization of CDDP to the lymph nodes. Our previous studies have shown successful drainage
of hyaluronan-cisplatin (HA-Pt) conjugates into the axillary lymph nodes with reduced
systemic toxicities after local injection in a breast cancer xenograft model in rodents (Cai et
al., 2008).
Pulmonary delivery of the HA-Pt conjugate to the lungs may be useful in the treatment of lung
cancer by reducing systemic toxicities and increasing CDDP deposition and retention within
lung tumors, surrounding lung tissues, and the mediastinal lymph. The purpose of this study
was to determine the pharmacokinetics and tissue distribution of a pulmonary delivered HA-
Pt conjugate relative to CDDP and compare these results to CDDP or HA-Pt conjugate
delivered intravenously.
2. Materials and Methods
2.1. Materials
Hyaluronan as sodium hyaluronate was purchased from Lifecore Biomedical (Chaska, MN);
All other reagents were purchased from Sigma Chemical Co. or Fisher Scientific (Waltham,
MA) and used without further purification. Human lung adenocarcinoma epithelial cell line
A549 was cultured according to ATCC recommendations.
2.2. Synthesis of hyaluronan-cisplatin (HA-Pt) conjugates
HA (35,000 g/mol, 100 mg) and CDDP (45 mg) were dissolved in Milli-Q water (20 mL) and
stirred in the dark for 3 days at ambient temperature (ca. 25°C). The reaction mixture was
filtered (0.2 μm nylon membrane) and dialyzed against ddH2O (10,000 MWCO; Pierce,
Rockford, IL) for 48 h at 4°C. Following dialysis, the crude product was concentrated and
stored as a 3.5 mg/mL solution, and the degree of CDDP substitution was determined on a
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platinum (Pt) basis by atomic absorption spectroscopy (AAS). The resulting conjugate is
referred to as HA-Pt for clarity, although the conjugate is Pt(NH3)2(H2O)OOC-HA (mixture
of mono- and diconjugated).
2.3. In vitro drug release
The in vitro release rate of the active hydrated form of cisplatin (cis-[Pt(NH3)2(H2O)2+]) from
HA-Pt conjugate was determined in ddH2O or PBS. HA-Pt conjugate of known CDDP
concentration was sealed a dialysis bag (MWCO 10,000, Pierce) and placed in a stirred water
bath (pH 7.4, 37°C) or PBS (140 mM, pH 7.4, 37°C). The bath volume (3 L) was replaced
every 4 h and the sink conditions were maintained at 37 °C and pH controlled by addition of
NaOH and HCl. Samples were taken from the dialysis bags at predetermined time points, and
remaining Pt concentration was determined by AAS. As a control, free CDDP diffusion from
the dialysis bag was also determined under the same sink conditions. All experiments were
conducted in triplicate and the results expressed as mean ± STD.
2.4. Cell toxicity
A549 cell line was seeded into 96-well plates (5000 cells/well) in Kaighn's Modified F12
medium supplemented with 10% fetal bovine serum and 1% L-glutamine. After 24 h, CDDP
or HA-Pt was applied (n = 12; 7 concentrations) and at 72 h post-addition, resazurin blue in
phosphate-buffered saline was applied to each well (final concentration of 5 μM). After 4 h,
the fluorescence was measured (ex 560 nm, em 590 nm; SpectraMax Gemini; Molecular
Devices, Sunnyvale, CA), and the IC50 was determined as the midpoint between negative (no
drug) and positive controls (no cells).
2.5. Pharmacokinetics and tissue distribution in rodents
Female Sprague-Dawley rats (250–300 grams) (Charles River Laboratories, Inc., Wilmington,
MA) were housed with free food and water access and on 12 h light/dark cycles in temperature
and humidity controlled rooms. The University of Kansas IACUC committee approved all
animal surgical and experimental procedures.
All surgical tools were autoclaved and MRE-033 tubing (Braintree Scientific; Braintree MA)
was ethylene oxide sterilized prior to use. Rats were anesthetized by isoflurane inhalation for
surgical procedures. Atropine (0.05 mg/kg) was given subcutaneously to prevent overactive
secretion of the trachea upon stimulation. The rat's body temperature was maintained at 37°C
during surgical procedures. MRE-033 tubing was surgically implanted in the jugular vein. After
exposing the trachea, a 25-gauge needle was used to make a small puncture in the trachea just
below the cricoid cartilage. MRE-033 tubing was inserted through the hole and secured just
above the bifurcation. Both cannulas were tunneled through to the back of the neck and the
incision was closed. Buprenorphrine (0.1 mg/kg) was given as post-operative care. The rats
were allowed to recover overnight before experimentation. For i.v. dosed rats, only a jugular
cannula was implanted.
Prior to instillation of CDDP or HA-Pt, rats were anesthetized by isoflurane inhalation and
positioned upright so that the lungs were in a vertical presentation. CDDP (3.5 mg/kg) or HA-
Pt (3.5 mg/kg equivalent of CDDP) in ca. 200 μL of saline was slowly injected through the
trachea cannula over 1 min, followed by a saline chase to correct for the cannula dead volume
(ca.10 μL). The rat remained upright for the following 4 min and was then removed from
anesthesia. Blood samples (200 μL) were taken from the jugular cannula at 5 min, 0.5, 1, 2, 4,
6, 8, 12, 24, and up to 96 h post dose. Blood was transferred to vials containing 2 μL of sodium
heparin and centrifuged to obtain plasma. The plasma was stored at −80°C until analysis. At
24 and 96 h post dose, the rats were euthanized by isoflurane overdose. Organs and lymph
nodes were harvested, washed in 0.9% saline, and stored at −80°C until analysis.
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Pharmacokinetic analysis was performed using data from individual rats for which the mean
and standard error of the mean (S.E.M.) were calculated for each group using WinNonlin®
software (Version 5.2, Pharsight Corporation, Mountain View, CA).
2.6. Atomic absorption spectroscopy (AAS) for CDDP
The in vitro release samples and plasma samples were diluted 200-fold and 10-fold in 0.1%
nitric acid, respectively. Tissue samples (100 mg) and lymph nodes (10 mg) were digested in
4.5% nitric acid at 80°C for 2 h and then homogenized (Tissue Tearor; BioSpec Products Inc,
Bartlesville, OK). All samples were centrifuged at 17,000 g for 20 min and the supernatants
were analyzed by AAS.
The Pt concentrations in the release samples and plasma, tissue, and lymph node samples were
analyzed on a Varian SpetrAA 220G atomic absorption spectometer (Palo Alto, CA, USA)
with a graphite furnace and partition tubes. Testing samples (21 μL) were injected by an
autosampler, followed by addition of 0.1% nitric acid (19 μL). A calibration curve of platinum
concentration was determined from 0 to 450 ppb in 0.1% nitric acid. The Pt recovery was
measured by spiking plasma/tissue blanks with CDDP or HA-CDDP (50 μg/g) and processing
as above. The furnace program was as follows: ramp 25 to 80 °C, hold 2 s; ramp to 120 °C,
hold 10 s; ramp to 1000 °C, hold 5 s; ramp to 2700 °C, hold 2 s; cool to 25 °C over 20 s. The
graphite partition tube was cleaned every 40 samples by baking at 2800 °C for 7 s. Argon was
used as the injection and carrier gas.
2.7. Lung tissue histology
For histological examination of lung tissue after lung administration, rats were euthanized at
24 h post instillation of HA-Pt, CDDP, or HA in saline, as described above. The lungs were
harvested and stored in 80% alcoholic formalin until analysis. Tissue processing for histology
and examination was performed in a blinded manner by a third party pathologist before
decoding.
2.8. Statistics
All tissue distribution and pharmacokinetic data were compared between CDDP (i.v. and
pulmonary instillation) and HA-Pt (i.v. and pulmonary instillation) groups using the two-tailed
student t-test. For all statistical analyses, p values less than 0.05 were considered significant.
3. Results and Discussion
3.1. Synthesis of HA-Pt conjugates
CDDP was conjugated to HA using a starting ratio of CDDP/HA ranging from 0.03 up to 0.70.
The conjugation efficiency decreased with the increase of CDDP/HA starting ratio due to the
poor solubility of CDDP in water and possibly due to the crowding of Pt on the HA polymer
at higher degrees of substitution and creation of hydrophobic regions. As shown in Table 1,
the conjugation efficiency was significantly decreased from 50.8% (0.5 w/w CDDP/HA) to
34.4% (0.7 w/w CDDP/HA). The HA-Pt conjugate used in the following animal studies had a
substitution degree of 25% (w/w). As shown in Fig. 1, one or more chlorides on CDDP can
hydrolyze and then replaced by carboxylate(s) on HA. The resulting conjugate is referred to
as HA-Pt for clarity, although the conjugate is Pt(NH3)2(H2O)OOC-HA (mixture of mono-
and diconjugated, Fig. 1). The released product is also referred to as CDDP for clarity and
comparision to the free drug, although the released product is a mixture of hydrolyzed and
chlorinated forms.
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3.2. In vitro CDDP release
The CDDP release rate was determined in PBS and water according to a reported protocol
(Jeong et al., 2008; Nishiyama and Kataoka, 2001). The CDDP release profiles showed psuedo
first order release kinetics with a half-life of 42 h in water and 10 h in PBS (Fig. 2). The Cl−
in PBS displaced CDDP rapidly and thus increased the release rate. The diffusion rate of free
CDDP (Pt) from the dialysis tubing was also determined. More than 90% of CDDP moved
across the dialysis membrane in 2 h (data not shown). A similar CDDP release profile from
cisplatin-incorporated hyaluronic acid nanoparticles was observed by Jeong et al. (Jeong et al.,
2008). Cisplatin was conjugated on to hyaluronan COOH groups via an ester bond (Fig. 1),
which was reversible due to its low nucleophilicity; and in vivo CDDP was slowly released as
its intact form from the HA-Pt conjugates.
3.3. Cell toxicity
HA-Pt conjugates had similar toxicities as compared to CDDP in the human lung cancer cell
line A549. There was no significant difference in cell toxicity (IC50 2 μg/mL, corresponding
to 7 μM) between HA-Pt and CDDP (Fig. 3). IC50 of CDDP in the A549 cell line was in good
agreement with the previously reported values from Cafaggi (IC50 6.87 μM) (Cafaggi et al.,
2007) and Rabik (IC50 9.7 μM) (Rabik et al., 2008). HA had no toxicity to A549 over the
concentration range examined (up to 10 mg/mL; data not shown). These results suggest that
the antitumor activity of CDDP was fully preserved after conjugation to HA. Over the time
period of the toxicity study, nearly all of the platinum would be released from the HA
conjugates. Agreeing with reported studies (Banzato et al., 2008;Brown, 2008), our results
indicate that synergistic or antagonistic effects due to hyaluronan are not evident. Other studies
determined that the conjugation of CDDP to gelatin or poly(γ, L-glutamic acid) reduced its
cytotoxicity in vitro. As reported by Tseng et al. (Tseng et al., 2009), when CDDP was
conjugated to gelatin, the IC50 value of gelatin-CDDP was 3.6-fold higher than free CDDP.
Poly(γ, L-glutamic acid)-cisplatin conjugate was less toxic than free CDDP in the human breast
cancer cell line Bcap-37 (Ye et al., 2006).
3.4. Pharmacokinetics and tissue distribution
The Pt concentration in the plasma or tissues was determined by the AAS. The calibration
curve was linear in the concentration range from 0 to 450 ppb (R2 > 0.99), with a limit of
detection of 5 ppb and a limit of quantification of 10 ppb (5% standard deviation). The Pt
recovery from HA-CDDP spiked tissues was: plasma 82 ± 4 % (mean ± std); lymph nodes 92
± 2%; bladder 88 ± 1%; brain 94 ± 0.3%; heart 97 ± 1%; kidneys 98 ± 1%; liver 100 ± 1%;
lung 94 ± 1%; muscle 95 ± 1%; spleen 97 ± 1%. The Pt recovery from CDDP spiked tissues
was: plasma 80 ± 3 % (mean ± std); lymph nodes 92 ± 6%; bladder 86 ± 3%; brain 93 ± 10%;
heart 93 ± 5%; kidneys 100 ± 2%; liver 100 ± 7%; lung 95 ± 8%; muscle 100 ± 5%; spleen 96
± 9%.
Similar Pt tissue concentrations (Fig. 4A) were observed in brain, heart, kidney, liver, muscle
and spleen 24 h post dose in both CDDP lung instillation (l.i.) and HA-Pt (l.i.) treated animals
(n = 5 CDDP l.i.; n = 3 HA-Pt l.i.). The total Pt concentration in the bladder was significantly
higher in the CDDP l.i. group 24 h post dose. At 96 h, there were statistically significant
differences in the Pt distribution in kidneys, liver and lungs for the HA-Pt lung instillation
group (Fig. 4B). The lung accumulation of Pt was 1.5-fold and 0.8-fold higher in the HA-Pt
l.i. group compared with the CDDP l.i. group (p < 0.05) at 24 h and 96 h, respectively. In order
to compare the Pt distribution in tissues between the l.i. and i.v. routes, CDDP (n = 4) and HA-
Pt (n = 3) were also administered as an i.v. bolus dose. As shown in Fig. 4 for i.v. groups,
significantly higher Pt concentrations were found in the liver and spleen but not in the lung
tissues for the HAPt i.v. group at both 24 h and 96 h. The Pt concentration in the bladder for
the CDDP i.v. group at 24 h was higher than that of the HA-Pt group. The results of the tissue
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distribution study (Fig. 4) indicated that the HA-Pt l.i. group had 5.7-fold and 1.2-fold higher
lung Pt concentrations than the CDDP i.v. group, at 24 h and 96 h, respectively.
The peak plasma concentrations (Cmax) for i.v. groups (both CDDP and HA-Pt) and the CDDP
l.i. group were achieved immediately post dose; while for the HA-Pt l.i. group, the Cmax reached
its maximum at 24 h (Fig. 5). The Cmax values were 9.0-, 54.0- and 0.7-fold higher for the
groups of CDDP i.v., HA-Pt i.v., CDDP l.i., respectively, when compared to Cmax of the HAPt
l.i. group. The first order input rate (Ka) in the HA-Pt l.i. group was significantly reduced
compared to the other treatment groups; the Pt plasma concentration in the HA-Pt l.i. group
gradually increased and reached a time to maximum concentration (Tmax) at 24 h (Fig. 5) and
then entered the elimination phase. The Pt plasma concentrations in the HA-Pt l.i. group were
higher than the corresponding concentrations in the CDDP l.i. group 4 h post dose.
Similar nodal distribution of Pt was found in the axillary and inguinal nodes at both 24 h and
96 h (Fig. 6) for the l.i. groups. The collected nodes included hilar, mediastinal, carinal, and
aortic nodes, which are the major lung draining lymph nodes. The Pt nodal concentration in
the HA-Pt l.i. group, reported as μg/g lymph node tissue, had a 1.9-fold increase compared to
the CDDP l.i. group at 24 h but showed no significant differences at 96 h. The Pt concentrations
in the draining lung surrounding nodes were similiar between CDDP i.v and HA-Pt i.v. groups.
When CDDP or HA-Pt conjugates were given intravenously, the Pt preferentially accumulated
in the axillary and inguinal nodes to a greater extent than the surrounding lung lymph nodes.
The most significant finding of localized concentration was in the lung lymph nodes, where Pt
was 1.1-fold higher in the HA-Pt l.i. group than the CDDP i.v. group at 24 h.
In order to compare the relative nodal concentrations and non-specific organ uptake, the ratio
of the Pt concentration in tissues to plasma was reported in Table 2. At 24 h, tissue/plasma
ratios for the HA-Pt i.v. group were slightly lower or similar to the ratios in the CDDP i.v.
group, except for the liver. The HA-Pt l.i. group had lower Pt concentrations in all the tested
organs compared to CDDP l.i. group. This ratio in the surrounding nodes draining the lung
was similar for all the i.v. groups and l.i. groups. Due to the high molecular weight of HA
(35,000 g/mol) and the slow release of Pt from HA-Pt conjugates in the lung, the tissue/plasma
ratio of the non-draining lymph nodes such as the axillary node and inguinal node was much
lower in the HA-Pt l.i. group than the CDDP l.i. group. At 96 h, the HA-Pt l.i. group had the
lowest tissue/plasma ratio in all the organs and tested lymph nodes for the four treatment groups
examined. Nephrotoxicity and neurotoxicity are clinically the most severe dose-limiting side-
effects of CDDP therapy. When comparing the tissue/plasma ratios in the brain and kidneys,
the HA-Pt l.i. group had a smaller ratio in both organs at 24 h and 96 h compared to the CDDP
i.v. group. Although the ratio in the lung was not significantly different between the groups of
CDDP l.i. and HA-Pt l.i. at 24 h, the ratios for the HA-Pt l.i. group and CDDP i.v. group at 24
h were 15.42 ± 2.70 and 4.40 ± 0.68, respectively.
The relative discrepancy is partially explained by the much higher plasma AUC for l.i. HA-Pt
compared to other treatments, as l.i. HA-Pt sustained much higher plasma concentrations of
Pt at 24 and 96 h than the other treatments. As indicated in Fig. 5, the Pt plasma concentration
at 96 h was 0.34 ± 0.06 and 1.24 ± 0.17 μg/mL for the CDDP i.v. and HA-Pt l.i. groups,
respectively. Thus the ratio of Pt in lung/plasma at 96 h for the HA-Pt l.i. group was only half
of the value of the CDDP i.v. group. The increased plasma concentrations at later time points
suggests that platinum is released slowly from the conjugates, which may reduce the acute
toxicity of CDDP therapy as the input rate and high Cmax immediately after i.v. dosing is
believed to lead to many of the toxic side-effects of chemotherapeutic agents (Chen and
Hasumi, 1995;Ikeda et al., 1998;Kurihara et al., 1996;Launay-Vacher et al., 2008).
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The plasma platinum concentrations were modeled using non-compartmental modeling
(WinNonlin®); and the pharmacokinetic parameters (the volume of distribution, Vz; the area
under the curve from time zero to 96 h, AUC0–96; the total body clearance, Cl; the peak plasma
concentration, Cmax; the mean residence time, MRT; and the terminal elimination half-life,
t1/2) were calculated and evaluated. CDDP i.v. exhibited a significantly higher Vz compared
to the HA-Pt i.v., likely due to the extensive tissue binding of free CDDP as opposed to a
polymer bound CDDP conjugate even though the half-life of CDDP release in vitro is a mere
10 h. With regard to the clearance of CDDP, the free CDDP (Mw = 300.05 g/mol) was cleared
from the body more rapidly compared to HA-bound CDDP (i.v. groups). It is likely due to the
smaller size and lower molecular weight and water solubility of CDDP, facilitating glomerular
filtration through the kidneys. In contrast, the active form of the drug can only be cleared after
cleavage from the hyaluronan polymer backbone. These pharmacokinetic parameters were
very similar to the results of free CDDP and CDDP-incorporating PEG-P(Glu) micelles using
the same noncompartment model (Uchino et al., 2005). In addition, the AUC0–96 of l.i. HA-
Pt treated group demonstrated a 0.6-fold increase in relative to i.v. CDDP treated group, which
could be explained by the sustained release characteristics of the conjugate over time. The
mean residence time and the terminal elimination half-time of HA-Pt l.i. group were 1.3-fold
and 1.0-fold higher than the CDDP i.v. group. The data from the lung instillation studies
suggests `flip-flop' pharmacokinetics of the HA-Pt conjugate, indicating the absorption of the
conjugate is the rate-limiting step and dissolution of the conjugate may be slow. In this case
the plasma concentration time curve is proportional to the rate of absorption. Therefore, the
i.v. and l.i. data demonstrated non-parallel slopes in the terminal elimination phase. It is likely
due to the depot effect of the polymer-drug conjugate, preventing the rapid distribution of the
drug into the system. There remained a significant amount of drug in the plasma at the
conclusion of the 96 h pharmacokinetic study as the absorption rate constant is much slower
than the elimination rate constant. The controlled release fashion of the HA-Pt conjugate when
used clinically could be significantly beneficial for patients with lung cancers by reducing the
treatment frequency through a increased dosing interval which could ultimately shorten the
hospital stay.
3.5. Lung tissue histology
Histological examination of lung tissue after l.i. administration revealed areas of moderate
inflammation characterized by infiltration of neutrophils, edema, and exudation of protein rich
fluid when either HA-Pt or CDDP were dosed (Fig. 7 A and B). Although patchy areas of lung
tissue elicited areas of inflammation, the majority of the airways remained clear. These doses
were also compared to lung tissue with only HA in saline dosed, which showed only mild
inflammation with a few small areas of neturophil infiltration (Fig. 7 C). With reduced
inflammation occurring when only HA was dosed, it is suggested that the majority of lung
inflammation was due to CDDP. Although lung inflammation occurred in these studies, it is
important to note that independent of what was instilled; all histological data revealed that the
animals were diagnosed with pneumonia. This suggests a major role of the method of delivery
in these histological results. Although studies have suggested that instilling at a volume of ca.
1 mL/kg body weight is suitable for delivery, this form of pulmonary delivery is not clinically
relevant. Even for jet nebulizers where up to 10 mL is delivered per 70 kg patients only ca.
0.14 mg/kg is delivered to the lung. Aerosol inhalation would be more suitable and practical
delivery method that may increase and optimize drug distribution throughout the lung. The
instillation method used here only concentrated the drug in portions of the lung eliciting patchy
areas of inflammation. An aerosolized delivery of HA-Pt would most likely result in more
optimal drug distribution in the lung as well as deposition deeper in the lung periphery with
increased drainage to lung lymph nodes.
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In conclusion, hyaluronan-cisplatin conjugate was successfully synthesized and the in vitro
antitumor activity of cisplatin was fully preserved after conjugation. Compared to conventional
CDDP i.v. infusion, the HA-Pt lung instillation group had not only higher Pt accumulations in
the lung tissues and the draining lung surrounding nodes but also demonstrated a sustained
release plasma profile with a reduced peak plasma concentration.
In future studies, we will examine the in vivo efficacy in orthotopic rodent models of lung
xenograft. In addition, a nebulized formulation is currently being developed that may further
optimize delivery and disposition. If these results are translatable into the clinic, a HA-Pt
localized pulmonary treatment could possibly lead to a relatively non-invasive, more effective
lung cancer treatment, which could have clinical utility in lung cancer patients.
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Synthesis and release of HA-Pt conjugates
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In vitro release of platinum from HA-Pt conjugates
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Cell toxicity of CDDP and HA-Pt conjugates
Xie et al. Page 13














Tissue distribution of CDDP and HA-Pt conjugates
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Pharmacokinetics intravenous vs. lung instillation
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Lymph node distribution intravenous vs. lung instillation
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Lung histology after instillation of (A) HA-Pt, (B) CDDP, and (C) HA in saline (24 h post
dose)
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Table 1
Conjugation efficiency of HA-Pt











Conjugation efficiency was calculated as (CDDP added/CDDP conjugated)* 100%
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